|
1
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hanemaaijer R, Verheijen JH, Maguire TM,
Visser H, Toet K, McDermott E, et al: Increased gelatinase-A and
gelatinase-B activities in malignant vs. benign breast tumors. Int
J Cancer. 2:204–207. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liotta LA: Tumor invasion and metastases -
role of the extracellular matrix: Rhoads Memorial Award lecture.
Cancer Res. 46:1–7. 1986.PubMed/NCBI
|
|
4
|
Lynch CC and Matrisan LM: Matrix
metalloproteinases in tumor-host cell communication.
Differentiation. 70:561–573. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Somiari SB, Shriver CD, Heckman C, Olsen
C, Hu H, Jordan R, Arciero C, Russell S, Garguilo G, Hooke J and
Somiari RI: Plasma concentration and activity of matrix
metalloproteinase 2 and 9 in patients with breast disease, breast
cancer and at risk of developing breast cancer. Cancer Lett.
233:98–107. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Leppä S, Saarto T, Vehmanen L, Blomqvist C
and Elomaa I: A high serum matrix metalloproteinase-2 level is
associated with an adverse prognosis in node-positive breast
carcinoma. Clin Cancer Res. 10:1057–1063. 2004.PubMed/NCBI
|
|
7
|
Mendes O, Kim HT and Stoica G: Expression
of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat
model. Clin Exp Metastasis. 22:237–246. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Baker EA, Stephenson TJ, Reed MW and Brown
NJ: Expression of proteinases and inhibitors in human breast cancer
progression and survival. Mol Pathol. 55:300–304. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bodey B, Bodey B Jr, Siegel SE and Kaiser
HE: Matrix metalloproteinases in neoplasm-induced extracellular
matrix remodelling in breast carcinoma. Anticancer Res.
21:2021–2028. 2001.PubMed/NCBI
|
|
10
|
González LO, Pidal I, Junquera S, Corte
MD, Vásquez J, Rodríguez JC, Lamelas ML, Merino AM, García-Muñíz JL
and Vizoso FJ: Overexpression of matrix metalloproteinases and
their inhibitors in mononuclear inflammatory cells in breast cancer
correlates with metastasis-relapse. Br J Cancer. 97:957–963.
2007.PubMed/NCBI
|
|
11
|
Talvensaari-Mattila A, Pääkkö P, Höyhtyä
M, Blanco-Sequeiros G and Turpeenniemi-Hujanen T: Matrix
metalloproteinase-2 immunoreactive protein: a marker of
aggressiveness in breast carcinoma. Cancer. 83:1153–1162. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jezierska A and Motyl T: Matrix
metalloproteinase-2 involvement in breast cancer progression: a
mini-review. Med Sci Monit. 15:RA32–RA40. 2009.PubMed/NCBI
|
|
13
|
Di Carlo A, Terracciano D, Mariano A and
Macchia V: Matrix metalloproteinase-2 and matrix
metalloproteinase-9 type IV collagenases in serum of patients with
pleural effusions. Int J Oncol. 26:1363–1368. 2005.PubMed/NCBI
|
|
14
|
Staack A, Badendieck S, Schnorr D, Loening
SA and Jung K: Combined determination of plasma MMP2, MMP9, and
TIMP1 improves the non-invasive detection of transitional cell
carcinoma of the bladder. BMC Urol. 6:192006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Incorvaia L, Badalamenti G, Rini G, Arcara
C, Fricano S, Sferrazza C, Di Trapani D, Gebbia N and Leto G:
MMP-2, MMP-9 and activin A blood levels in patients with breast
cancer or prostate cancer metastasis to the bone. Anticancer Res.
27:1519–1525. 2007.PubMed/NCBI
|
|
16
|
Jinga DC, Blidaru A, Condrea I, Ardeleanu
C, Dragomir C, Szegli G, Stefanescu M and Matache C: MMP-9 and
MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast
cancer: correlations with prognostic factors. J Cell Mol Med.
10:499–510. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stankovic C, Konjevic G, Gopcevic K, Jovic
V, Inic M and Jurisic V: Activity of MMP-2 and MMP-9 in sera of
breast cancer patients. Pathol Res Pract. 206:241–247. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Quaranta M, Daniele A, Coviello M, Venneri
MT, Abbate I, Caringella ME, Di Tardo S, Divella R, Trerotoli P, Di
Gennaro M, Schittulli F, Fransvea E and Giannelli G: MMP-2, MMP-9,
VEGF and CA 15.3 in breast cancer. Anticancer Res. 27:3593–3600.
2007.
|
|
19
|
Ranuncolo SM, Armanasco E, Cresta C, Bal
De Kier Joffe E and Puricelli L: Plasma MMP-9 (92 kDa-MMP) activity
is useful in the follow-up and in the assessement of prognosis in
breast cancer patients. Int J Cancer. 106:745–751. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Köhrmann A, Kammerer U, Kapp M, Dietl J
and Anacker J: Expression of matrix metalloproteinases (MMPs) in
primary human breast cancer and breast cancer cell lines: New
findings and review of the literature. BMC Cancer.
9:1882009.PubMed/NCBI
|
|
21
|
Li HC, Cao DC, Liu Y, Hou YF, Wu J, Lu JS,
Di GH, Liu G, Li FM, Ou ZL, Jie C, Shen ZZ and Shao ZM: Prognostic
value of matrix metalloproteinases (MMP-2 and MMP-9) in patients
with lymph node-negative breast carcinoma. Breast Cancer Res Treat.
88:75–85. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Talvensaari-Mattila A, Pääkkö P and
Turpeenniemi-Hujanen T: MMP-2 positivity and age less than 40 years
increases the risk for recurrence in premenopausal patients with
node-positive breast carcinoma. Breast Cancer Res Treat.
58:287–293. 1999.PubMed/NCBI
|
|
23
|
Talvensaari-Mattila A, Pääkko P,
Blanco-Sequeiros G and Turpeenniemi-Hujanen T: Matrix
metalloproteinase-2 (MMP-2) is associated with the risk for a
relapse in postmenopausal patients with node-positive breast
carcinoma treated with antiestrogen adjuvant therapy. Breast Cancer
Res Treat. 65:55–61. 2001. View Article : Google Scholar
|
|
24
|
Atik E, Akansu B, Bakaris S and Aban N:
Expression of cyclooxygenase-2 and its relation to histological
grade, inducible nitric oxide synthase, matrix metalloproteinase-2,
CD-34, Caspase-3, and CD8 in invasive ductal carcinoma of the
breast. Saudi Med J. 31:130–134. 2010.
|
|
25
|
Nassar A, Radhakrishnan A, Cabrero IA,
Cotsonis G and Cohen C: COX-2 expression in invasive breast cancer:
correlation with prognostic parameters and outcome. Appl
Immunohistochem Mol Morphol. 15:255–259. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sivula A, Talvensaari-Mattila A, Lundin J,
Joensuu H, Haglund C, Ristimaki A and Turpeenniemi-Hujanen T:
Association of cyclooxygenase-2 and matrix metalloproteinase-2
expression in human breast cancer. Breast Cancer Res Treat.
89:215–220. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
de la Torre J, Sabadell MD, Rojo F, Lirola
JL, Salaricru S, Reventos J, Ramón y Cajal S and Xercavins J:
Cyclo-oxygenase type 2 is dysregulated in breast ductal carcinoma
in situ and correlates with poor outcome. Eur J Obstet Gynecol
Reprod Biol. 151:72–76. 2010.PubMed/NCBI
|
